Type 1 Diabetes Research Advances Toward Insulin Independence
Significant progress is being made in the treatment of type 1 diabetes (T1D), with new therapies aiming to achieve insulin independence for patients. Innovations include Sanofi's Tzield, the first disease-modifying therapy for pediatric patients with stage 3 T1D, and SAB Biotherapeutics' SAB-142, which combines human and animal-derived antibodies to improve glycemic control. Eledon Pharmaceuticals is developing tegoprubart, which has shown promise in achieving insulin independence in patients post-cellular transplant surgery. These developments are part of a broader effort to move beyond traditional insulin-based treatments, offering new hope for patients with T1D. 
